摘要
目的探讨骨髓细胞microRNA-100表达水平对急性髓细胞白血病(AML)患者的预后评估价值。方法选取核型正常AML(CN-AML)患者154例,采用荧光定量RT-PCR法检测骨髓细胞microRNA-100的表达水平,将数值大于等于中位数者归为高表达组,低于中位数者归为低表达组。比较microRNA-100高表达组与低表达组患者的临床特征,包括性别、年龄、FAB分型、Hb、WBC、PLT、原始细胞比例、FLT3-ITD基因突变、NPM1基因突变、化疗后完全缓解情况等。随访48个月,观察并比较两组患者总生存、无事件生存率。结果与高表达组患者比较,低表达组患者的FAB分型M4、M5型比例较高(P<0.05),Hb水平较低(P<0.05),原始细胞比例较低(P<0.05)。两组患者性别、年龄、WBC、PLT、FLT3-ITD基因突变、NPM1基因突变、化疗后完全缓解情况比较均无统计学意义(均P>0.05)。microRNA-100低表达组患者总生存率、无事件生存率均低于高表达组患者(均P<0.05)。结论 microRNA-100低表达或是AML患者预后差的评估指标。
Objective To assess the prognostic value of miR-100 expression in patients with cytogenetically normal acute myeloid leukemia（CN-AML）.Methods miR-100 expression was detected by real-time quantitative PCR in bone marrow blasts from 154 patients with CN-AML.Patients with miR-100 expression level higher than the median were defined as high expression group.The age,sex,white cells counts（WBC）,hemoglobin,platelet counts（PLT） and therapeutic response were compared between high and low expression groups.The overall survival（OS） and event free survival（EFS） were analyzed after 48 months of follow-up.Results Patients with low miR-100 expression had lower hemoglobin and lower percentage of blasts,but higher frequency of FAB M4/5 subtypes.There were no significant differences in age,sex,WBC and PLT,FLT3-ITD and NPM1 gene mutations and complete remission rate between high and low expression groups.Patients with low miR-100 expression had poorer OS and EFS than those with high expression.Conclusion miR-100 expression may be used as a prognostic biomarker for patients with CN-AML.
出处
《浙江医学》
CAS
2017年第19期1646-1648,1734,共4页
Zhejiang Medical Journal
